Philanthropic Partnerships
A catalytic investment to transform evidence into impact.
Why This Work Is Needed
Once a drug becomes generic, there is often no institutional owner positioned to fund additional research into new uses, regulatory submissions, or awareness efforts. As a result, evidence for repurposed generics remains fragmented and underused, leaving potentially beneficial treatments out of reach for patients.
This is not a gap in science alone. It is a structural gap created by market incentives.
Philanthropy makes it possible to close that gap.
Why This Model is Catalytic
Philanthropic dollars unlock overlooked opportunities that could deliver impact now.
Traditional Drug Development
Prioritizes patentable, high-cost drugs
Driven primarily by commercial incentives
Long, expensive development timelines for new products
Fragmented evidence across studies and indications
No coordinated pathway for advancing repurposing opportunities
Reboot Rx Model
Advances off-patent, evidence-backed therapies
Focused on unmet patient needs and available evidence
Builds on existing safety and efficacy data
Systematic, transparent evidence aggregation
Provides independent coordination across evidence, evaluation, and pathway
Philanthropic support provides the coordination, rigorous evaluation, and awareness work needed to inform clinical decision-making around promising treatments.
Our Early Progress
In just a few years, Reboot Rx has built an AI-powered platform to systematically identify high-potential cancer treatments among existing generic drugs. This work has surfaced a focused set of opportunities supported by strong clinical evidence.
We are now working with partners such as the National Cancer Institute, the Veterans Health Administration, and leading cancer centers to support clinical evaluation and awareness. Momentum is strong, and expanding this work now will accelerate the next wave of opportunities.
What Your Support Enables
Evidence Identification & Prioritization
Large-scale evidence reviews
Structured candidate assessments of repurposing opportunities
Algorithmic scanning of new generic drugs
Clinical Awareness & Pathway Analysis
Development of clinician-facing, decision-ready evidence materials
Analyses clarifying regulatory, guideline, and payer pathways
Evidence Evaluation & Research Collaboration
Observational data analyses and clinical studies
Research partnerships with national networks and cancer center
Infrastructure for Scale
Expansion of our AI-powered evidence synthesis platform
Capacity to evaluate new opportunities on an ongoing basis
Our work is further strengthened by pro bono contributions from leading legal, scientific, and advisory organizations, increasing the leverage of philanthropic investment.
The Impact This Work Will Drive
Philanthropic support enables Reboot Rx to:
Accelerate evaluation of overlooked generic drugs for new cancer uses
Strengthen the clinical evidence base through research with leading institutions
Inform guideline inclusion and payer pathways that influence clinical use
Equip clinicians with clear, balanced evidence to support decision-making
Reduce system-level friction that limits access to safe, cost-effective treatments
This work strengthens the structural pathways needed for evidence-supported, affordable treatments to be considered within clinical decision-making.
Ways to Partner With Us
General operating support is the most powerful way to partner with Reboot Rx, enabling us to respond quickly to emerging evidence, advance high-potential opportunities, and sustain the infrastructure required for large-scale impact.
Additional ways to engage include:
Program and project support
Fund specific evidence evaluation efforts, clinical studies, or priority repurposing programs.Strategic, multi-year partnerships
Collaborate on multi-year initiatives that expand the opportunity pipeline and support deeper evidence development.
Get Involved
If you are a foundation, family office, or individual donor, we welcome a conversation.
Acknowledgment of Philanthropic Support
Reboot Rx has received support from philanthropic partners committed to advancing evidence-informed innovation in cancer care, including:
Arnold Venture · Lyda Hill Philanthropies · Pershing Square Foundation
alongside other strategic supporters